OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Experimental & Clinical Cancer Research is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression	302
Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis	245
Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer	242
LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma	237
Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer	215
Correction: Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway	202
Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer	175
The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway	169
Targeting FAM83D triggers tumor cell senescence via cGAS-STING signaling activation and reprograms TAMs to combat glioma	151
CircFOXK2 promotes hepatocellular carcinoma progression and leads to a poor clinical prognosis via regulating the Warburg effect	151
The RP11-417E7.1/THBS2 signaling pathway promotes colorectal cancer metastasis by activating the Wnt/β-catenin pathway and facilitating exosome-mediated M2 macrophage polarization	145
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway	144
Ropivacaine as a novel AKT1 specific inhibitor regulates the stemness of breast cancer	143
M2 macrophage-secreted KYNU promotes stemness remodeling and malignant behavior in endometrial cancer via the SOD2-mtROS-ERO1α-UPRER axis	136
LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2	134
Circulating CD137⁺Treg cells and LOX-1⁺PMN-MDSCs as biomarkers of immunotherapy resistance in (R/M) HNSCC patients	133
EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance	127
The importance of being CAFs (in cancer resistance to targeted therapies)	126
The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors	125
SEC23A confers ER stress resistance in gastric cancer by forming the ER stress-SEC23A-autophagy negative feedback loop	116
Combination of dual JAK/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer	114
TRIM6 ablation reverses ICB resistance in MSS gastric cancer by unleashing cGAS-STING-dependent antitumor immunity	113
Fast detection, a precise and sensitive diagnostic agent for breast cancer	106
tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma	103
Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells	102

CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response	101
Correction: circular RNA circATP9A promotes non-small cell Lung cancer progression by interacting with HuR and by promoting extracellular vesicles-mediated macrophage M2 polarization	100
Retraction Note: TRIM11 overexpression promotes proliferation, migration and invasion of lung cancer cells	98
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma	97
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer	97
The DCDC2/ENO1 axis promotes tumor progression and immune evasion in intrahepatic cholangiocarcinoma via activating FGL1-LAG3 checkpoint	93
Targeting homologous recombination deficiency in uterine leiomyosarcoma	93
Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models	92
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma	91
FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer	91
Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG	90
Correction: ZEB1-mediated biogenesis of circnipbl sustains the metastasis of bladder cancer via Wnt/β-catenin pathway	89
CCNY-mediated phosphorylation and TET2-BACH1-driven DNA demethylation activate PRC1 to augment NSCLC progression	89
Retraction Note: Tripartite motif-containing 14 (TRIM14) promotes epithelial-mesenchymal transition via ZEB2 in glioblastoma cells	86
Novel APLNR antagonist candesartan induces tumor vascular normalization through ROS/cGAS/STING axis and augmented sunitinib response in breast cancer	85
CRISPR-Cas9 knockout screening identifies KIAA1429 as an essential gene in Ewing sarcoma	85
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer	84
Plasma-derived extracellular vesicles miR-335–5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma	84
Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade	82
CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer	82
Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening	80
Mechanism of cancer-associated fibroblast-driven thyroid cancer dedifferentiation via the ZFP57-PKM2 axis-mediated lactate secretion and therapeutic intervention with resveratrol	79
Correction: GPR119 agonist enhances gefitinib responsiveness through lactate-mediatedinhibition of autophagy	78
Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop	78
CSRP2 promotes the glioblastoma mesenchymal phenotype via p130Cas-mediated NF-κB and MAPK pathways	78
Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer	78
Correction: LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond	77
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer	77
Correction: Deliberation concerning the role of M1-type macrophage subset in oral carcinogenesis	74
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma	73
Inhibition of RACGAP1 sensitizes triple-negative breast cancer cells to ferroptosis by regulating CPT1A-dependent fatty acid metabolism	73
Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment	73
The reprogramming impact of SMAC-mimetic on glioblastoma stem cells and the immune tumor microenvironment evolution	73
Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers	73
USP43 promotes gemcitabine resistance by regulating cholesterol homeostasis through E2F1 stabilization in bladder cancer	72
MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis	72
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?	72
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth	71
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth	71
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models	70
Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation	69
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma	69
Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair	68
Correction: Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment	68
PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer	68